Community update Roche: Discontinuation of emugrobart for SMA
We regret to inform that Roche has decided not to advance emugrobart (an investigational anti-myostatin antibody, also known as GYM329) into Phase III development for SMA, leading to the discontinuation of the MANATEE clinical study.
Roche informs that this decision is not related to any safety concerns, but rather to data indicating that emugrobart in combination with risdiplam did not meaningfully improve motor function compared to risdiplam alone.